Balversa 4 mg

BALVERSA 4 MG tablets contain erdafitinib, a targeted therapy used to treat specific types of cancer. This medication is designed to inhibit certain proteins involved in cancer cell growth.

BALVERSA 4 MG tablets are primarily used in the treatment of advanced or metastatic cancers that have specific genetic mutations. Erdafitinib, the active ingredient, targets these mutations to help slow down the growth and spread of cancer cells. Patients should consult their healthcare provider to determine if this medication is suitable for their condition.

Common effects of BALVERSA 4 MG tablets may include fatigue, nausea, and changes in appetite. Some patients may also experience dry skin or vision changes. These effects can vary from person to person, and not everyone will experience them.

BALVERSA 4 MG tablets should be handled with care and stored as directed. It is important to follow the prescribed dosage and administration instructions provided by a healthcare professional. Patients should inform their healthcare provider about any other medications they are taking to avoid potential interactions.

BALVERSA 4 MG tablets may interact with certain medications, including those that affect liver enzymes. It is important to discuss all current medications with a healthcare provider to ensure safe and effective use. Alcohol and other substances may also interact with this medication.